权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Multicytokine-producintg mononuclear cell therapy for cancer patients

针对癌症患者的产生多细胞因子的单核细胞疗法

基本信息

批准号：
04670788
负责人：
KATANO Mitsuo
金额：
$ 1.34万
依托单位：
Saga Medical School
依托单位国家：
日本
项目类别：
Grant-in-Aid for General Scientific Research (C)
财政年份：
1992
资助国家：
日本
起止时间：
1992 至 1993
项目状态：
已结题

来源：
https://kaken.nii.ac.jp/en/grant/KAKENHI-PROJECT-04670788/
关键词：
Malignant tumors OK-432 Cytokine Adoptive immunothrapy Intratumor injection Mononuclear cells TGIF Frozen spleen cells

项目摘要

Based on the experimental findings, multicytokine-producing cytotxic mononuclear cells(MCCM) therapy was performed for 1)patients with gastric cancer, 2)those with recurrent or inoperable brain tumors, and 3)those with advanced head and neck cancers. In this report, clinical effects and safety of the MCCM therapy were studied and summarized. Results : 1) OK-432-activated peripheral blood mononuclear cells(MCCM : 10^7 cells) were locally administered to the tumor site for the treatment of 22 patients with gastric cancer before operation, and the resulted specimens were examined macroscopically and hitopathologically. Disappearance, extensive necrosis and focal necrosis of the tumors were found in 1, 3 and 4 cases, respectively. No particular side effects were encountered. In addition, a case with postoperative recurrent hepatic metastasis received intra-arterial injection of cryopreserbed splenn-derived ononuclear cells(MCCM). In this case, speed of the tumor grouth was slightly suppres … More sed. 2)MCCM therapy was done in 18 cases with head and neck cancers and histopapthological examination was completed in 9 out of the 18 cases. Complete response, partial response and mild response were detected in 3, 5 and 1 cases, respectively. A patient with neck cancer showing cystic formation received intratumor injection of MCCM alone. She showed a significant reduction of the tumor and a rapid decrease of CEA levels in the cystic fluid. In addition, two patients who received intratumor injection of cryopreserved allogeneic spleen-derived MCCM had a remarkable reduction of tumors. Curative operation was fortunately performed in one of the 2 patients. A transient fever immediately after the MCCM therapy was often ecncountered.3)Five patients with recurrent and/or inoperable glioblastoma received the MCCM therapy. Patients receiveing the MCCM therapy showed a siginificant long mean survival times compared with patients not receiveing the MCCM therapy (MCCM vs control : 26 months vs 12 months). However, severe side effects including high fever and hypotension were encoutered. Less

根据实验结果，对1)胃癌患者，2)复发或不能手术的脑肿瘤患者，3)晚期头颈癌患者进行了多细胞因子产生的细胞毒单个核细胞(MCCM)治疗。本文对MCCM疗法的临床疗效和安全性进行了研究和总结。结果：1)将OK-432激活的外周血单核细胞(MCCM：10~7细胞)用于22例胃癌术前局部治疗，并对标本进行大体观察和组织病理学检查。肿瘤消失1例，广泛坏死3例，局灶性坏死4例。没有遇到特别的副作用。此外，1例术后复发的肝转移患者接受了经动脉注射冷冻保存的脾来源的单个核细胞(MCCM)。在这种情况下，肿瘤生长的速度稍微抑制了…更精致了。2)18例头颈癌患者接受了MCCM治疗，其中9例完成了组织病理学检查。完全缓解3例，部分缓解5例，轻度缓解1例。1例表现为囊变的宫颈癌患者仅接受了MCCM瘤内注射。她显示肿瘤明显缩小，囊液中CEA水平迅速下降。此外，接受肿瘤内注射冷冻保存的同种异体脾来源的MCCM的两名患者的肿瘤显著减少。幸运的是，其中一名患者接受了根治性手术。3)5例复发和/或无法手术的胶质母细胞瘤患者接受了MCCM治疗。接受MCCM治疗的患者与未接受MCCM治疗的患者相比，平均生存时间显著延长(MCCM与对照组：26个月与12个月)。然而，包括高烧和低血压在内的严重副作用被抑制。较少